| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 10052022 | The Journal of Urology | 2005 | 7 Pages |
Abstract
Combination cisplatin based neoadjuvant chemotherapy may benefit patients with locally advanced bladder cancer. Gemcitabine/cisplatin has replaced methotrexate, vinblastine, doxorubicin and cisplatin as the regimen of choice in patients with good renal function. The optimal regimens for the medically unfit patient and second line chemotherapy remain undefined. The development of targeted therapies, less toxic regimens and improved cytotoxic agents are necessary to improve outcomes.
Related Topics
Health Sciences
Medicine and Dentistry
Nephrology
Authors
JONATHAN E. ROSENBERG, PETER R. CARROLL, ERIC J. SMALL,